NIH Study Section Review

I am writing to set the record straight. In a letter in the Nov. 13, 1995, issue of The Scientist [page 13], Paul K. Strudler, a National Institutes of Health grants administrator, refers to my article entitled "How Federal Funding Mechanisms Stifle Basic Biomedical Research (The Scientist, Aug. 21, 1995, page 10) as evidence that I believe that NIH study sections are not reviewing basic science applications adequately. In fact, I wrote that new innovative research-that is, R01s -- whether in

Written byEdith Rosenberg
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

In fact, I wrote that new innovative research-that is, R01s -- whether in basic or applied research, are not being adequately funded. Strudler quotes verbatim from the introduction to my article that "applied science, which requires the collaboration of many diverse people with their support staff and specialized instruments, has generally received the lion's share of research funds distributed by NIH," and bases his comment that it is my belief that study sections review basic science applications inadequately on this.

In fact, this statement is not my unsubstantiated opinion but a summary of factual information about NIH funding. There have been a great many objective investigations of where NIH grant monies went during recent years. Four or five of the studies have been featured in The Scientist, and more have been referred to. It is misleading to present factual information as my belief, particularly when this is done in order ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies